Rick Matthews/LikedIn
Mar 9, 2026, 13:49
Rick Matthews: Looking Beyond Clot Clearance in Long-Term Management After DVT
Rick Matthews, Senior Vascular Consultant at Argon Medical Devices, Inc., shared on LinkedIn:
”We talk a lot about ‘clearing clot today’ with modern mechanical thrombectomy/PMT options, but the long game is what patients live with: recurrent ipsilateral DVT risk, valve injury, chronic outflow obstruction, and structured follow-up.
Are you routinely documenting Villalta at 3–6 months after DVT (and repeating at ~12 months), or is it still inconsistent across services?
PTS symptoms often reflect the net effect of obstruction plus reflux plus microvascular injury—so the pathway has to be stepwise.
My simple escalation triggers (baked into any VTE program):
- Villalta ≥10 / meaningful functional limitation
- Venous claudication
- Skin changes or ulcer
- New/worsening swelling – rule out recurrent DVT first”
Stay updated with Hemostasis Today.
-
Sep 17, 2026, 02:36Wolfgang Miesbach: Effectiveness of Avatrombopag in ITP Treatment
-
Sep 17, 2026, 02:34Aleksandar Sič: The Endothelium and Cardiovascular Toxicity in Blood Cancers
-
Sep 16, 2026, 15:45Matthew Hazell: A Brilliant Explanation of Phenotype vs Genotype Using a LEGO House
-
Sep 16, 2026, 15:23Ahmad Al-Ramahi: Presenting the Military Pharmacists Blood Training Course at the FIP World Congress
-
Sep 16, 2026, 15:21HIT Reimagined: Can 12-Lipoxygenase Inhibition Stop Immune Thrombosis?
-
Sep 16, 2026, 14:42Ruchi Punamia: Beyond the Blood Bank and The Clinical Impact of Apheresis
-
Sep 16, 2026, 14:06Kalyan Roy: Celebrating Apheresis, Advancing Care, Saving Lives
-
Sep 16, 2026, 13:38Andrew Zapfel: Advancing Sickle Cell Disease Care and Research
-
Sep 16, 2026, 13:30Thirunavukkarasu Angappan: Why Plasma-Derived Factor VIII Still Matters for Inhibitor Patients